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Key points: 
• A meta-analysis was conducted to evaluate the effects of isolated oral taurine 
ingestion on endurance performance and to assess the contribution of i) the dose and 
ii) the supplementation period to the ergogenic effect.     
• Human endurance performance can be improved by a ‘small’ magnitude after orally 
ingesting a single dose of taurine in varying amounts (1 g - 6 g). 
• Further research is needed to establish the effects of the oral taurine dose on 
endurance performance and which populations would benefit most from its 
supplementation.   
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Abstract 
Background Taurine is central to many physiological processes, some of which are 
augmented by exogenous supply and have the potential to facilitate endurance performance; 
however, its independent effects on performance have not been systematically analysed.   
Objective To evaluate the effects of isolated oral taurine ingestion on endurance performance 
and to assess the contribution of i) the dose and ii) the supplementation period to the 
ergogenic effect.     
Methods A search was performed using various databases in September 2017. The studies 
were screened using search criteria for eligibility. 10 peer-reviewed articles were identified 
for inclusion. A sub-analysis of time-to-exhaustion (TTE) trials (n = 7) was also performed. 
The effects of i) dose and ii) the acute (single dose) or chronic (> 1 day) supplementation 
periods were assessed using meta-regression. The doses of taurine ranged from 1-6 g/day and 
were provided in single doses and for up to two weeks among a range of subjects.   
Results Taurine ingestion improved overall endurance performance (Hedges’ g = 0.40, 95% 
CI = 0.12 to 0.67, P = 0.004), which was similar in TTE trials (Hedges’ g = 0.43, 95% CI = 
0.12 to 0.75, P = 0.007). There were no differences between acute or chronic 
supplementation for the full sample (P = 0.897) or the TTE group (P = 0.896). The dose of 
taurine did not moderate its effect on endurance performance (P > 0.05).   
Conclusion Human endurance performance can be improved by orally ingesting a single 
dose of taurine in varying amounts (1 g - 6 g). 
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1. Introduction 
Taurine, a sulfur-containing amino acid, is one of the primary ingredients in popular energy 
drinks [1], as well as most meats and seafood [2]. Taurine is the most abundant free amino 
acid in mammalian tissue, accounting for 50-60 % of the free amino acid pool [3] and is 
available to facilitate a variety of biological processes that can support endurance exercise 
performance. For example, once inside the muscle, taurine assists with sarcoplasmic 
reticulum Ca2+ handling [4,5], with improvements in muscle performance attributed to 
taurine-facilitated Ca2+ handling of both cardiac and skeletal myocytes [3]. An anti-oxidative 
role has also been ascribed to taurine, which facilitates taurine’s stabilising effects in the 
mitochondrial matrix, thus improving the efficiency of ATP turnover in the muscle cell [6]. 
Indeed, prevention of taurine uptake in taurine transporter (TauT) knockout mice 
significantly reduces time to exhaustion [7]. It is thought that one, or a combination of these 
mechanisms, can enhance endurance performance by increasing the capacity of human 
muscle over prolonged periods. However, despite the known physiological effects of taurine, 
less is understood about the efficacy of taurine supplementation for enhancing endurance 
performance in human participants.  
 
The lack of historical interest in isolated taurine supplementation and human performance is 
somewhat surprising, given its inclusion in popular energy drinks, and its purported 
contribution to their ergogenic effects. Indeed, a recent meta-analysis demonstrated that the 
dosage of taurine, as opposed to caffeine, when co-ingested in energy drinks explained their 
effects on different types of exercise performance [8]. However, the authors did not include 
investigations using isolated taurine supplementation, focussing on co-ingested energy drinks 
alone. This is problematic because this does not remove the potential in-vivo interaction 
5 
 
between taurine and other ingredients, such as caffeine, which have been identified in animal 
models [9]. Furthermore, this approach overlooks research that has investigated higher 
isolated doses of taurine (4-6 g) compared to that of typical of energy drinks (1-2 g). This is 
important to understand since individual studies have reported that higher doses (6 g/day for 
seven days) can increase markers of aerobic performance, such as maximal oxygen uptake 
(?̇?𝑉O2max) [10]. Therefore, this study systematically reviewed and meta-analysed all peer-
reviewed studies that have provided human subjects with isolated taurine. The aim of the 
meta-analysis was to determine the effects on endurance performance and the importance of 
the dose and supplementation period to the ergogenic effects.     
 
2. Methods 
2.1 Search strategy  
All literature that investigated the effect of taurine on endurance performance was searched 
and obtained using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement guidelines, with a pre-determined search strategy [11]. There was no 
limit on the status or language of the publication and the final searches were performed in 
PubMed, Science Direct and SPORTDiscus (EBSCO) on 01.09.17. The search terms used 
were ‘taurine AND exercise OR taurine AND performance OR ‘taurine AND ‘aerobic’.  
 
2.2 Study selection 
Once all of the articles were identified, two reviewers screened the titles and abstracts for 
inclusion, removing any duplicates. ‘Other sources’ were also identified, such as hard-copies 
of taurine-related research from conferences or industry studies, all of which were excluded. 
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The reference lists of the initial papers were reviewed independently by two authors (MW 
and OJ), which did not reveal any additional papers. The remaining articles were then 
assessed by MW and OJ against the initial search criteria. To be included in this analysis, the 
studies must have: i) administered oral taurine to humans of any age, without co-ingestion 
with other supplements or drugs and ii) evaluate exhaustive protocols > 3-min. Of the 
remaining papers, some were further removed for the reasons outlined in Figure 1. In part, 
this included papers that had co-ingested taurine with other supplements, such as caffeine or 
polyphenols. As endurance performance encompasses a variety of activities, we limited this 
review to three forms of exhaustive exercise modality. These were: time-to-exhaustion (TTE) 
trials; time-trials (TT) and power output during closed-loop tasks. Overall effects (i.e. 
combination of all modalities) and effects of the TTE modality were considered for the 
eventual analysis. Tests, such as the Bruce protocol or adapted versions and graded exercise 
tests to exhaustion, were considered as TTE trials based on the commonly reported metric of 
test duration. Time-trials were converted to speed (m/s) for analysis. We removed any forms 
of exercise that were non-exhaustive or performed for less than 3-min, based on the 
fundamental understanding that exercise to exhaustion over this period of time will require 
predominant contributions from aerobic metabolism, irrespective of the intensity [12].  
 
*****Insert Figure 1 near here***** 
 
2.3 Data extraction and quality assessment  
Data were extracted independently by two authors (MW and OJ) and entered into a custom 
excel spreadsheet. Collected data included: i) characteristics of the sample (sex, health status, 
age, training status); ii) study design; iii) taurine dose; iv) duration of supplementation; v) 
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performance outcomes; and vi) bias. Risk of bias was assessed by two authors (MW and OJ) 
according to Cochrane collaboration guidelines [13]. Where details of the study were unclear, 
the authors were contacted for information of confirmation of the method. Publication bias 
was also accounted for by plotting the effect size as a percentage against the standard error 
(SE) for each study (Figure 3). 
 
2.4 Statistical analysis 
Data analyses were performed by one author (MW). Raw data were extracted in the form of a 
mean, SD and sample size for the meta-analysis. Publicly available software 
(WebPlotDigitizer, Version 3.12) was used to extrapolate any unreported values from figures 
to raw mean and SD data. The overall meta-analysis of endurance performance was 
performed in Statistical Package for the Social Sciences (SPSS, Version 22, IBM Corp., 
Armonk, NY, USA), including all 10 studies. The effect sizes and inverse-variance weights 
were calculated according to published equations Lipsey and Wilson [23]. Data were 
analysed with a fixed-effects model, with heterogeneity assessed using the I2 statistic. 
Hedges’ g and 95% confidence intervals were used to express the standardised mean 
differences between taurine and placebo groups across studies. To assess the effects of 
taurine on TTE, a second meta-analysis was performed on 7 of the studies. Meta-regressions 
were performed on both the full (n = 10) and partial data sets (n = 7) using the continuous 
variable of dose, referring to the daily dose (g/day) of taurine provided to the participants in 
the study, as the moderating variable. A sub-group analysis was also performed on both 
datasets based on the type of supplementation regime (acute or chronic). The magnitudes of 
the effects were assessed based on the thresholds of: 0.2, 0.5 and 0.8 for small, moderate and 
large, respectively [24]. Statistical significance was set at P < 0.05 for all analyses.      
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3. Results 
3.1 Study selection 
The initial searches retrieved 3431 articles, plus an additional 24 studies through other 
sources. These were reduced to 2799 after removal of duplicates. Further screening left 122 
full-text articles over. Searches of their reference lists did not reveal any missing papers. On 
the basis of the inclusion criteria, 112 articles were removed from the 122. Therefore, 10 
papers were included in the final meta-analysis and 7 in the TTE analysis (see Figure 1). 
Effects for the TT and study measuring power output are presented for demonstrative 
purposes. 
 
3.2 Study characteristics 
The characteristics of the 10 included studies are summarized in Table 1. The studies 
included a total of 116 participants, comprising both males and females of varying age, 
training and health status. Seven of the studies were cross-over designs, whilst three were 
independent group designs. The range of taurine that was orally administered across studies 
was 1 g/day to 6 g/day and this was well-balanced between acute (single dose; n = 6) and 
chronic (multiple doses > 1 day; n = 4) supplementation regimes. There were no adverse 
events noted in any of the studies.  
 
*****Insert Table I near here***** 
 
3.3 Overall meta-analysis 
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The results of the overall meta-analysis are reported in Figure 2. Overall, there was a small-
to-moderate improvement in endurance performance with taurine compared to placebo 
(Hedges’ g = 0.40, 95% CI = 0.12 to 0.67, P = 0.004). The I2 statistic demonstrated 29.4% 
heterogeneity. The meta-analysis of the TTE group (n = 7) also showed a small-to-moderate 
effect of taurine on performance (Hedges’ g = 0.43, 95% CI = 0.12 to 0.75, P = 0.007), with 
0% heterogeneity (I2).  
 
3.4 Sub-group analysis 
The sub-group analysis demonstrated no difference (P = 0.897) in the effects of taurine on 
endurance performance between acute (Hedges’ g = 0.39, 95% CI = 0.13 to 0.64, P = 0.003) 
and chronic (Hedges’ g = 0.42, 95% CI = 0.07 to 0.75, P = 0.016) supplementation for the 
full sample. The same was true for the TTE group, with no differences (P = 0.896) in the 
effects of taurine on endurance performance between acute (Hedges’ g = 0.45, 95% CI = 0.11 
to 0.77, P = 0.007) and chronic (Hedges’ g = 0.42, 95% CI = 0.07 to 0.75, P = 0.016) 
supplementation.   
 
3.5 Meta-regression 
The dose of taurine provided to participants across all ten studies (b = 0.053, P = 0.431) or 
the TTE group (b = 0.0013, P = 0.98) did not moderate the outcome of taurine on endurance 
performance.   
 
*****Insert Figure 2 near here***** 
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3.6 Risk of bias 
The studies included had a generally low or unclear risk of bias, with one study [10] not 
counterbalancing or stating any blinding procedures. Similarly, allocation concealment and 
blinding were unclear in another study [14]. Figure 3 shows that publication bias analysis 
(standard mean differences and standard error relationship) was symmetrical, with no 
outliers.  
 
*****Insert Figure 3 near here***** 
 
4. Discussion 
The main findings of this analysis were that oral taurine ingestion improved endurance 
performance by a ‘small’ amount (Hedges g 0.4), with marginally larger effects (Hedges g 
0.43) found for TTE trials (Figure 2). The secondary sub-group analysis did not demonstrate 
differences between acute and chronic supplementation regimes, indicating that taurine’s 
effects were not determined by the duration of the supplementation period. Furthermore, 
there was no influence of the taurine dose on its performance effects, suggesting that doses as 
low as 1 g or as high as 6 g can be effective in increasing endurance performance. 
Collectively, these results indicate that endurance performance can be improved to a similar 
magnitude (small) after providing 1 g of taurine in a single oral dose or 6 g for up to two 
weeks. Despite Hedges’ g indicating a small effect of taurine on endurance exercise 
performance, these changes could confer practically or clinically-relevant effects. For 
example, training-induced improvements in Bruce protocol exercise duration are typically 
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‘large’ among heart failure patients (ES ~ 1.1; [25-26]). Increases in time to exhaustion 
among adults of mixed training status are also ‘small’ after ingestion other ergogenic aids, 
such as caffeine (~ 0.4; [27]). The small effect sizes noted herein, therefore, represent a 
substantial portion of the typical enhancements observed in endurance performance after 
months of training or are equally ergogenic as caffeine.  
 
The current meta-analysis was based on studies providing isolated doses of taurine and not 
those co-ingesting with other supplements. Interestingly, our analysis confirms the 
suggestions of a previous meta-analysis [8], where taurine was assumed to explain the 
ergogenic effects of energy drinks. Only one study from the current analysis was shared 
between the two meta-analyses, owing to the number of experimental groups included by 
Kammerer et al. [18]. It was important to conduct our analysis because it was possible that 
taurine’s effects were dependent on the in-vivo interaction with caffeine [9], which could not 
be ruled out unless studies providing isolated doses of caffeine were independently analysed. 
Therefore, the combined results of this study and the previous meta-analysis [8], have 
systematically identified that the potential interactions between caffeine and taurine are not 
necessary to improve human endurance performance.        
 
The current meta-regression analysis identified that the dose of taurine did not affect the 
outcome on endurance performance. This is important for potential users of taurine, who are 
unlikely to incur any additional benefit from consuming large doses. Indeed, coupling this 
with the finding that single doses were equally effective as chronic loading periods, means 
that improvements in endurance performance can be achieved without long-term ingestion or 
the requirement for doses that are closer to the most tolerable upper limit of 10 g/day [28]. 
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Whilst this should be treated as preliminary evidence (n = 10 studies), potential taurine users 
might consider this when designing their supplementation plan for endurance exercise, which 
will be more cost and time-effective. Further research examining the effects of different doses 
of taurine on endurance performance among the same participants would add to the current 
body of literature and corroborate these findings.      
 
The reasons for improvements in endurance performance after oral taurine supplementation 
are remain speculative; however, recent studies have revealed that acute supplementation can 
increase lipolysis and reduce the contribution from glycolytic metabolism, thereby altering 
the fuel utilisation and metabolic efficiency of exercise [29]. Others ascribe the effects or 
taurine to an anti-oxidative role, which facilitates taurine’s stabilising effects in the 
mitochondrial matrix, thus improving the efficiency of ATP turnover in the muscle cell [6]. 
However, these effects require corroboration among human participants. Whist the 
mechanisms of taurine’s action are likely to become clearer in the near future, it is likely that 
a combination of factors explain its ‘small’ effects of endurance performance.   
 
This analysis is not without limitations. Firstly, it is noted that our study selection 
incorporated findings from both healthy volunteers and heart failure patients, of varying ages. 
It is possible that the health or training status of the subjects would influence the effects of 
taurine; however, there was not sufficient data to investigate this hypothesis. As identified in 
Figure 2, the largest effect sizes were shared between healthy and non-healthy subjects, 
inferring that this would not have affected the outcome of the analysis. It is, therefore, 
possible that taurine supplementation can facilitate endurance performance, irrespective of 
the participants’ health status. The number of studies included in this analysis was, however, 
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quite small, yet homogenous, as indicated by the null effects of the heterogeneity testing. 
However, it would be useful for more studies to be performed to investigate the effects of 
taurine on endurance performance, particularly among subjects from different populations. 
The lower representation of TTs in the overall analysis and the contrast in findings between 
these studies [17,20] also highlights the need for further research using this model of 
performance.   
 
5. Conclusion 
The implications of this study are that human endurance performance can be improved by 
orally ingesting taurine of varying doses (1 g - 6 g), with as little as a single acute dose. This 
can be viewed as a relatively simple and inexpensive way of increasing endurance capacity to 
improve athletic performance or clinical outcomes. The population that would most benefit 
from this supplement remains unclear, given the range of subjects used across the 10 selected 
articles, and future research should also investigate the effects of oral taurine supplementation 
across participants of varying age, health and training status.  
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Figure legends 
 
 
 
 
Figure 1. The process and reasons for study selection (n = 10) in the final meta-analysis. 
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Figure 2. Effect of taurine on endurance performance. Green circles = low risk of bias; red 
circles = high risk of bias; blank spaces = unclear risk of bias.  
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Figure 3. Risk of bias, determined by the relationship between standard mean difference 
(SMD) and standard error (SE) of the SMD.  
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Table I. Summary of studies included in the meta-analysis for the effects of taurine on endurance 
performance (n = 10).  
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Study Design Sample Dose Duration Performance type Outcome 
       
Lee et al. 
(2003)[14] 
Independent groups, 
single-blind, randomised  
Healthy, male college students (n = 6 per group). 
Age 20.2 ± 0.6 vs. 21.2 ± 0.4 years. 
4 g /day 14 days Treadmill running @ 75% ?̇?𝑉O2max 8.1% ↑ in TTE 
       
Zhang et al. 
(2004)[10] 
Crossover (not 
counterbalanced) 
Healthy sedentary males (n = 11). Age range 18 - 20 
years. 
6 g (3 x 2 g/day) 7 days ?̇?𝑉O2max test cycling 2.6% ↑ exercise time; 2% ↑ 
?̇?𝑉O2max; 3.8% ↑ power output. 
       
Rutherford et 
al. (2010)[15] 
Crossover, double-blind, 
randomised 
Healthy, endurance-trained males (n = 11). Age 27.2 
± 1.5 years. 
1.66 g (single 
dose) 
1-h pre-
exercise 
90-min cycle @ ~65% ?̇?𝑉O2max, 
followed by TT @ 5 kJ/km body 
mass 
NS 4.6% ↑ in taurine vs. placebo 
       
Beyranvand et 
al. (2011)[16] 
Independent groups, 
double-blind, 
randomised 
Elderly heart failure patients male and female (n = 
15 vs. 14). Age 60.9 ± 5.7 vs. 60.3 ± 7.5 years. 
1.5 g (3 x 500 
mg/day) 
14 days Bruce protocol or adapted Bruce 
protocol 
17.5% ↑ exercise time in 
combination of Bruce protocols 
       
Balshaw et al. 
(2013)[17] 
Crossover, double-blind, 
randomised 
Well-trained male middle distance runners (n = 8). 
Age 19.9 ± 1.2 years. 
1 g (single dose) 2-h pre-
exercise 
3 km treadmill TT 1.7% ↑ TT performance  
       
Kammerer et 
al. (2014)[18] 
Crossover, double-blind, 
randomised 
 
Healthy male soldiers (n = 14). Age 20 ± 1 years 
1 g (single dose) 45-min 
pre-
exercise 
?̇?𝑉O2max test treadmill NS ↓ 1.2% ?̇?𝑉O2max or 0.6% ↓ TTE 
in ?̇?𝑉O2max test 
       
Milioni et al. 
(2016)[19] 
Blinded, crossover, 
randomised  
Healthy, recreationally-trained males (n = 17). Age 
25 ± 6 years. 
6 g (single dose) 1.5-h pre-
exercise 
TTE @ 110% ?̇?𝑉O2max 2.9% NS ↑ in TTE @ 110% ?̇?𝑉O2max 
       
Ward et al. 
(2016)[20] 
Crossover, double-blind, 
randomised 
Healthy, well-trained male athletes (n = 11). Age 
34.6 ± 11.5 years.  
1 g (single dose) 2-h pre-
exercise 
4 km cycling TT NS ↓ 1% in TT performance 
       
Ahmadian et 
al. (2017)[21] 
Independent groups, 
double-blind, 
randomised  
Elderly heart failure patients (sex not mentioned) (n 
= 8). Age 60.1 ± 5.4 vs. age 60.1 ± 8.3 years. 
1.5 g (3 x 500 
mg/day) 
14 days Adapted Bruce Protocol 25.7% ↑ exercise time; 22.6 % ↑ 
distance covered 
       
Warnock et al. 
(2017)[22] 
Crossover, single-blind, 
randomised 
Healthy, recreationally-trained males (n = 7). Age 
20.8 ± 0.9 years. 
50 mg/kg body 
mass (single dose)  
1.5-h pre-
exercise 
3 x Wingate repeated sprint 14% ↑ mean peak power; 14.3% ↑ 
peak power; 9%↑ mean power 
       
Note: TT = time-trial; TTE = time-to-exhaustion; NS = non-significant.  
 
